Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Página 1 a partir de 33 resultados
Isotretinoin in Treatment of COVID-19
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The study is a randomized interventional comparative Phase III trial. The duration of the trial for each subject is expected to be 3 months. The duration for each individual subject includes one-month study treatment and 3 months follow-up time. Recruitment of subjects will start in April 2020.
150
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 (Randomized)
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The study is a randomized interventional comparative Phase III trial. 1000 adult male and female patients with positive COVID-19 diagnosis and fulfilling the below outlined inclusion criteria will be enrolled into the study.
Isotretinoin(13cis RA) may be able to inhibit COVID 2019 entry via down
Proviral DNA as a Target for HIV-1 Resistance Analysis
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
A prospective longitudinal observational study, the objective is to observe and describe the prevalence of INRT, INNRT, Protease and INIS mutations detected by proviral DNA in patients with virologic failure and low level viremia.
Inclusion/Exclusion: Our Study will include only patients with HIV
Effects of ART Simplification on Inflammatory Markers in coRis (AIR)
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
During treated HIV infection, higher levels of the inflammatory and coagulation markers interleukin-6 (IL-6), D-dimers, and high-sensitivity C-reactive protein (hs-CRP) are associated with an increased risk of cardio-vascular disease (CVD), cancer, and all-cause mortality. While ART decreases IL-6,
Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Toxicity associated with use of nucleoside reverse transcriptase inhibitors (NRTIs) for the treatment of VIH-infection has prompted increasing interest in new antiretroviral treatment strategies without NRTIs (nuc-sparing regimens).
Ritonavir boosted protease inhibitors (PI/r) like, lopinavir,
Safety and Therapeutic Efficacy of mAb VRC01 During ATI in Early Treatment During Acute HIV Infection
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The study agent, VRC-HIVMAB060-00-antibody (AB), was manufactured for the VRC by the Vaccine Pilot Plant operated by Leidos Biomedical Research, Inc, formerly SAIC-Frederick, Inc, Frederick, MD. Specific manufacturing information is included on the product vial labels and Certificates of Analysis
Dolutegravir Impact on Residual Replication
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
ART effectively suppresses HIV-1 viremia but in most patients, virus rebounds within 2-3 weeks of stopping ART. ART is unable to cure HIV due to the persistence of virus as long-lived latently infected cells, residual virus replication and anatomical reservoirs. Understanding the contribution of
Clinical Implications of HIV Low-level Viremia at Times of Highly Active Antiretroviral Treatment Regimens
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
The underlying study is a retrospective analysis of HIV-1 positive patients treated with antiretroviral therapy from Essen since 2004. Stored samples obtained for routine diagnostics will be used to analyze the gag gene, the V3-region and immune cells from selected patients. By comparing different
Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Extremely low levels of HIV reservoirs are achievable in some chronically-infected patients durably controlled with cART. Despite the multiplicity and heterogeneity of factors governing the persistence of HIV reservoirs, such low levels of HIV reservoirs seem necessary, though probably not
Targeted Clinical Strategies and Low Level Viraemia (LLV) in Boosted Protease Inhibitor Therapy
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Phase of Study: Non-Drug Study
Objectives:
1. Primary To investigate the causes of low level viraemia (LLV) in HIV-infected individuals with no PI resistance associated mutations (RAMs) on conventional genotyping who have a detectable plasma HIV viral load (pVL) and report >95% adherence* to their
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Justification: The interest of treating HIV infection with a single molecule has been clear for a long time. Many clinical trials have been testing the efficacy of such a strategy, mainly using a boosted protease inhibitor (PI). Despite the remaining doubts about low level viremia, viral control in
DRV/r + RPV QD: Efficacy and Toxicity Reduction
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Pilot, phase III prospective, randomized, open-label, multicentric controlled study, which will offer a novel dual-therapy regimen including RPV 25mg + DRV 800mg/rtv 100mg QD to HIV+ subjects with suppressed viremia.
132 HIV+ subjects will be randomized, 1:1, to switch to RPV+DRV/r versus continue
Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
AIDS continues to be a major global health priority. Although important progress has been achieved in preventing new HIV infections and in lowering the annual number of AIDS-related deaths, the number of people living with HIV worldwide continued to grow in 2008, reaching an estimated 33.4 million.
DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
O mais completo banco de dados de ervas medicinais apoiado pela ciência
- Funciona em 55 idiomas
- Curas herbais apoiadas pela ciência
- Reconhecimento de ervas por imagem
- Mapa GPS interativo - marcar ervas no local (em breve)
- Leia publicações científicas relacionadas à sua pesquisa
- Pesquise ervas medicinais por seus efeitos
- Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes
Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas
